Posters

Efficacy and safety of topical cyclosporine following LASIK for myopia in perimenopausal women

Poster Details

First Author: M.Elgharieb EGYPT

Co Author(s):    K. Zaky              

Abstract Details

Purpose:

To determine whether cyclosporine (0.05%) can effectively and safely resolve dry eye induced by LASIK in perimenopause women.

Setting:

Ophthalmology department, Faculty of Medicine, Suez Canal University Hospital, Ismailia, Egypt.

Methods:

This prospective, randomized, single-center clinical study comprised 80 myopic eyes of 40 perimenopause women scheduled to undergo bilateral LASIK using a VISX&trade S4 CustomVue&trade laser (AMO). No patients have symptoms, signs, or treatment of dry eye preoperatively. After surgery, all women were instructed to take standard postoperative LASIK medication. Women were randomly divided into 2 equal groups: a study group received topical cyclosporine 0.05%, twice daily, starting one day after surgery and continuing for 1 month and a control group received no cyclosporine treatment. Study visits were occurred pretreatment (baseline) before surgery, and at, 1 day, 1 week and 1, 3, and 6 months after surgery. Efficacy and safety were evaluated by tear film breakup time (TBUT), Schirmer, s test, assessments of ocular dryness symptoms, patient satisfaction, uncorrected visual acuity and refraction.

Results:

For 6 month follow up, in the control group, the mean postoperative Schirmer,s test values and TBUT values decreased from the baseline to 10 mm,13 sec. at 1 week,11 mm, 14 sec. at 1 month, then the mean Schirmer,s test value and TBUT became 13 mm, 15 sec. at 3 month and at 6 month, but in the study group, the mean postoperative Schirmer,s test values and TBUT values were approximately constant, 15 mm,17 sec. at1 week; 16 mm, 18 sec. at 1 month; 17 mm, 19 sec. at 3 month and at 6 month. The differences between study group and control group were statistically significant (P≤ 0.05). In the control group, 5 patients (10eyes) (25%) complained from symptoms of dryness, but no one had symptoms of dryness in the study group. At the 6-month visit, the mean spherical equivalent was closer to Plano in the both groups. The visual acuity was significantly better in the cyclosporine-treated eyes compared to the control eyes (P<0.04). Patient satisfaction was higher (90%) in the study group than (75%) in the control group. The difference between study group and control group was statistically significant (P =0.03).No adverse events from cyclosporine were noted.

Conclusions:

Topical cyclosporine (0.05%) twice a day after surgery, starting the day after surgery and continued for 1 month, can safely and effectively resolve dry eye induced by LASIK in perimenopause women. It also improved visual outcomes. A thick, stable tear improves vision and may explain the significantly better uncorrected visual acuity in the cyclosporine treated eyes. FINANCIAL INTEREST: NONE